紫杉醇联合顺铂治疗48例晚期鼻咽癌近期疗效分析  

Clinical Study of Paolitexel plus Cisplatin in the Treatment of Advanced Nasopharyngeal Carcinoma

作　　者：陈露[1] 金风[1] 董红敏[1] 陈海霞[1] 曾英[1] 苟晓霞[1] 

机构地区：[1]贵阳医学院附属医院肿瘤科,贵州贵阳550004

出　　处：《四川肿瘤防治》2007年第4期252-254,共3页Sichuan Journal of Cancer Control

摘　　要：目的：评价晚期鼻咽癌（NPC）患者应用紫杉醇与顺铂联合化疗的临床疗效及安全性。方法：2003年6月-2005年8月采用紫杉醇联合顺铂治疗晚期鼻咽癌48例。中位化疗周期数3周期（2周期-5周期）。紫杉醇（PTX）135mg/m^2,静脉滴注d1;顺铂（DDP）80mg/m^2,静脉滴注d1-2,21天为一个周期。结果：可评价疗效48例,CR6例（12.5%）,PR19例（39.6%）,NC 14例（29.1%）,PD9例（18.7%）,总有效率（CR＋PR）52.1%,中位缓解期（DFS）为6.5（2-12）个月,中位肿瘤进展时间（TTP）7.6（2-14）个月。主要毒性为骨髓抑制、胃肠道反应和关节肌肉疼痛,Ⅲ度-Ⅳ度白细胞减少发生率为18.7%,无严重并发症发生。结论：紫杉醇联合顺铂治疗晚期鼻咽癌有较好的疗效,且不良反应可以耐受。Objective： To evaluate the clinical response of paolitexel and cisplatin for patients with advanced nasopharyngeal carcinoma,and to assess the safety of paclitaxel based combination chemotherapy.Methods： From June 2003 to August 2005,48 patients with advanced nasopharyngeal carcinoma were treated by alliance of paclitaxel and cisplatin.The mean number of cycles was 3（range 2-5）,PTX 135mg/m^2 d1,ivgtt,DDP 80mg/m^2 d1-2,ivgtt.The cycle was repeated every 21 days.Results： The overall response rate（CR＋PR） was 52.1%（CR 6 cases,PR 19 cases,NC 14 cases and PD 9 cases）.The mean time of DFS was 6.5 months（range 2 to 12 months）.The median TTP was 7.6 months（range 2 to 14 months）.The main side effects included bone marrow depression,emesis,nausea,and pain of joint and muscle.The rate of leukocytopenia with Ⅲ to Ⅳ degree was 18.7%.No severe complications happened.Conclusion： The regimen of paclitaxel plus cisplatin is active in treatment of advanced nasopharyngeal carcinoma with an acceptable drug tolerance.

关 键 词：紫杉醇 顺铂 晚期鼻咽癌 药物治疗 

分 类 号：R739.63[医药卫生—肿瘤]